Focused ultrasound shows promise against deadliest brain tumor
Summary: Focused ultrasound treatments show promise in the fight against glioblastoma brain cancer. Sonodynamic therapy may also help treat other difficult-to-treat cancers.
Source: University of Virginia
An innovative use of focused ultrasound being pioneered at the University of Virginia School of Medicine is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
The technique hits cancer cells with a drug that sensitizes them to sound waves, then blasts them with focused ultrasound. The sound waves create tiny bubbles inside the cancer cells, causing them to die.
The work is early, with researchers testing the concept on cell samples in lab dishes. But their results suggest the technique has “substantial potential for treatment of malignant brain tumors and other challenging oncology indications,” such as lung cancer, breast cancer and melanoma, the researchers report in a new scientific paper. They predict the technique will be particularly useful in treating cancers in sensitive parts of the body that are difficult to access.
“Sonodynamic therapy with focused ultrasound offers a new therapeutic approach to treating patients with malignant brain tumors,” said UVA Health neurosurgeon Jason Sheehan, MD, PhD. “This approach combines two approved options, [the drug] 5-ALA and focused ultrasound, to produce a powerful tumoricidal effect on several different types of glioblastomas.”
Glioblastomas are the most common malignant brain tumors in adults. They are inevitably fatal, typically within 12 to 18 months of diagnosis. The shortage of effective treatments for this aggressive cancer means new approaches are needed desperately.
To evaluate the potential of their new focused ultrasound technique, the UVA researchers looked at its effects on both rat and human cell samples. They examined the benefits of the “sonosensitizing” drug, 5-ALA, and focused ultrasound individually and in combination, and they found that the pairing was far more effective than either alone. The drug reduced the number of viable cancer cells by 5%, while focused ultrasound reduced it by 16%. Together, the reduction was 47%.
“Focused ultrasound has the potential to improve outcomes for patients with complex brain tumors and other neurosurgical pathologies,” Sheehan said. “We may be at the tip of the iceberg in terms of intracranial indications for focused ultrasound.”
Busting Cancer With Bubbles
Many applications of focused ultrasound rely on the technology’s ability to create tiny points of heat inside the body to burn away harmful cells, or to damage cells enough to provoke an immune response. Sheehan’s approach is notable in that it takes another tack, destroying cancer cells without generating heat.
To test out the new technique, the researchers had to develop custom equipment so they could perform the focused ultrasound research on the cell samples. They did this from scratch, using a 3D printer and software at the Charlottesville-based Focused Ultrasound Foundation, a longtime supporter of focused ultrasound research at UVA and elsewhere.
The researchers say the new platform will advance focused ultrasound research in the future. Using it, scientists can quickly screen cell types and sonosensitizing drugs like the one used in UVA’s study. It will also be a benefit in pre-clinical and clinical testing in people, they say.
Pioneering Focused Ultrasound
While the sonosensitizing research is in its earliest phases, Sheehan is launching a separate glioblastoma clinical trial in people using a different focused ultrasound approach. That study will evaluate the technology’s potential to open the brain’s protective barrier briefly so that doctors can deliver treatments to the tumor that they normally can’t.
Sheehan’s research is part of a broad effort at UVA to explore the potential of focused ultrasound to treat various types of diseases. For example, UVA researchers are examining the technology’s ability to treat breast cancer and epilepsy.
Pioneering research by UVA neurosurgeon Jeff Elias, MD, already paved the way for the federal Food and Drug Administration to approve focused ultrasound to treat essential tremor, a common movement disorder, and tremor caused by Parkinson’s disease. Focused ultrasound treatment for those conditions is now available to appropriate patients. Learn more about focused ultrasound at UVA.
Glioblastoma Results Published
Sheehan and his colleagues have published their initial glioblastoma results in the Journal of Neuro-Oncology. The research team consisted of Kimball Sheehan, Darrah Sheehan, Mohanad Sulaiman, Frederic Padilla, David Moore, Sheehan and Zhiyuan Xu. Padilla and Moore are employed by the Focused Ultrasound Foundation.
The research was recognized as a gold medal winner in basic science by the AANS/CNS Tumor Section.
In addition, Sheehan and colleagues have seen positive results using a different sonosensitizer, fluorescein, in brain tumor preclinical models. The work also was recently published in the Journal of Neuro-Oncology.
About this neuroscience research article
University of Virginia
Josh Barney – University of Virginia
The image in the public domain.
Original Research: Closed access
“Investigation of the tumoricidal effects of sonodynamic therapy in malignant glioblastoma brain tumors”. by Kimball Sheehan, Darrah Sheehan, Mohanad Sulaiman, Frederic Padilla, David Moore, Jason Sheehan & Zhiyuan Xu.
Journal of Neuro-Oncology doi:10.1007/s11060-020-03504-w
Investigation of the tumoricidal effects of sonodynamic therapy in malignant glioblastoma brain tumors
Glioblastoma is the most common primary brain tumor; survival is typically 12–18 months after diagnosis. We sought to study the effects of sonodynamic therapy (SDT) using 5-Aminolevulinic acid hydrochloride (5-ALA) and high frequency focused ultrasound (FUS) on 2 glioblastoma cell lines.
Rat C6 and human U87 glioblastoma cells were studied under the following conditions: 1 mM 5-ALA (5-ALA); focused ultrasound (FUS); 5-ALA and focused ultrasound (SDT); control. Studied responses included cell viability using an MTT assay, microscopic changes using phase contract microscopy, apoptotic induction through a caspase-3 assay, and apoptosis staining to quantify cell death.
SDT led to a marked decrease in cell extension and reduction in cell size. For C6, the MTT assay showed reductions in cell viability for 5-ALA, FUS, and SDT groups of 5%, 16%, and 47%, respectively compared to control (p
Sonodynamic therapy resulted in appreciable glioblastoma cell death as compared to 5-ALA or FUS alone. The approach couples two already FDA approved techniques in a novel way to treat the most aggressive and malignant of brain tumors. Further study of this promising technique is planned.